



## Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

CHICAGO--(BUSINESS WIRE)--Dec. 27, 2023-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit "Events" on the investor relations page of the Company's website at [www.xerispharma.com](http://www.xerispharma.com).

### About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit [www.xerispharma.com](http://www.xerispharma.com), or follow us on [X](#), [LinkedIn](#), or [Instagram](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20231227139846/en/>

Allison Wey  
Senior Vice President, Investor Relations and Corporate Communications  
[away@xerispharma.com](mailto:away@xerispharma.com)

Source: Xeris Biopharma Holdings, Inc.